Horizon Pharma plc Form 4 June 24, 2015

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB** Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

**OMB APPROVAL** 

response...

subject to Section 16. Form 4 or Form 5 obligations may continue.

See Instruction

Check this box

if no longer

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* Hoelscher Paul W.

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

(Last)

(First) (Middle) Horizon Pharma plc [HZNP]

(Check all applicable)

C/O HORIZON PHARMA

PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD

(Street)

(State)

3. Date of Earliest Transaction (Month/Day/Year)

Director X\_ Officer (give title below)

10% Owner Other (specify

below)

EVP, CFO

(Zin)

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year)

06/23/2015

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

DUBLIN, L24

(City)

| (City)                               | (State)                              | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |  |   |        |             |  |  |   |  |  |
|--------------------------------------|--------------------------------------|--|--|---|--------|-------------|--|--|---|--|--|
| 1.Title of<br>Security<br>(Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year)                      | 3.<br>Transactic<br>Code<br>(Instr. 8) | 4. Securit<br>on(A) or Dis<br>(Instr. 3, 4) | sposed | of (D)      | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |  |  |
| Ordinary<br>Shares                   | 06/23/2015                           |  | M                                      | 20,000                                      | A      | <u>(1)</u>  | 20,000   | D  |   |  |  |
| Ordinary<br>Shares                   | 06/23/2015                           |  | F                                      | 8,799                                       | D      | \$<br>34.27 | 11,201   | D  |   |  |  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

### Edgar Filing: Horizon Pharma plc - Form 4

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactic<br>Code<br>(Instr. 8) | 5. Number of or Derivative Securities Acquired (A or Disposed (D) (Instr. 3, 4, and 5) | Expiration<br>(Month/Da | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                    | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |  |
|---|---|---|---|--|--|-------------------------|--|--------------------|---|--|
|   |   |   |   | Code V                                 | (A) (D)  | Date<br>Exercisable     | Expiration<br>e Date                                     | Title              | Amount<br>or<br>Number<br>of Shares                                 |  |
| Restricted<br>Stock<br>Units                        | <u>(1)</u>  | 06/23/2015                              |   | M                                      | 20,0   | 00 (2)                  | <u>(2)</u>   | Ordinary<br>Shares | 20,000  |  |

# **Reporting Owners**

Relationships Reporting Owner Name / Address

Director 10% Owner Officer Other

Hoelscher Paul W. C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN, L24

EVP, CFO

### **Signatures**

/s/ Miles W. McHugh, Attorney-in-Fact

06/24/2015

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- The restricted stock units vest in four annual installments of 20,000 shares, on each anniversary of the vesting commencement date (June 23, 2014).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2